Prescription patterns in patients with systolic heart failure at hospital discharge: Why beta blockers are underprescribed or prescribed at low dose in real life?

International Journal of Clinical Practice

Volumn 61, Issue 2, 2007, Pages 225-230

  Yilmaz, Mehmet B ^a,c   Refiker, M ^b   Guray, Y ^b   Guray, U ^b   Altay, H ^b   Demirkan, B ^b   Caldir, V ^b   Korkmaz, S ^b  

^a CUMHURIYET UNIVERSITY   (Turkey)

^b Yuksek Ihtisas Education and Research Hospital   (Turkey)

^c Pulur Mah   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; NITRATE; SPIRONOLACTONE; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG INDICATION; FEMALE; FREQUENCY ANALYSIS; HOSPITAL DISCHARGE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; SYSTOLIC HEART MURMUR;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGE FACTORS; CASE-CONTROL STUDIES; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 33847011736     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01157.x     Document Type: Article

References (25)

1. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-15.
2. McAlister FA, Teo KK, Taher M et al. Insights into the contemporary epidemiology and outpatient management of congestive heart failure. Am Heart J 1999; 138: 87-94.
3. Rodeheffer RJ, Jacobsen SJ, Gersh BJ et al. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 1993; 68: 1143-50.
4. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302.
5. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
6. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
7. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-7.
8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
9. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy. Clinical Quality Improvement Network Investigators. Arch Intern Med 1996; 156: 1669-73.
10. Mejhert M, Holmgren J, Wandell P, Persson H, Edner M. Diagnostic tests, treatment and follow-up in heart failure patients - is there a gender bias in the coherence to guidelines? Europ J Heart Fail 1999; 1: 407-10.
11. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997; 157: 2460-4.
12. Hunt SA, Baker DW, Chin MH et al. A report of the American College of Cardiology American Heart Association task force on practice guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure). Circulation 2001; 104: 2996-3007.
13. Bellotti P, Badano LP, Acquarone N et al. Specialty related differences in the epidemiology, clinical profile, management and outcome of patients hospitalized for heart failure. The OSCUR study. Eur Heart J 2001; 22: 596-604.
14. Smith NL, Chan JD, Rea TD et al. Time trends in the use of beta-blockers and other pharmacotherapies in older adults with congestive heart failure. Am Heart J 2004: 148: 710-7.
15. Komajda M, Follath F, Swedberg K et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464-74.
16. Karlson BW, Herlitz J, Hjalmarson A. Impact of clinical trials on the use of beta blockers after acute myocardial infarction and its relation to other risk indicators for death and 1-year mortality rate. Clin Cardiol 1994; 17: 311-6.
17. Sueta CA, Bertoni AG, Massing MW et al. Managed care patients with heart failure: spectrum of ventricular dysfunction and predictors of medication utilization. J Card Fail 2005; 11: 106-11.
18. Bertoni AG, Duren-Winfield V, Ambrosius WT et al. Quality of heart failure care in managed Medicare and Medicaid patients in North Carolina. Am J Cardiol 2004; 93: 714-8.
19. Muntwyler J, Cohen-Solalb A, Freemantlec N, Eastaughc J, Clelandd JG, Follatha F. Relation of sex, age and concomitant diseases to drug prescription for heart failure in primary care in Europe. Eur J Heart Fail 2004; 6: 663-8.
20. Rywika MT, Stefan L, Rywikb SL et al. A survey of outpatient management of elderly heart failure patients in Poland - treatment patterns. Int J Cardiol 2004; 95: 177-84.
21. Delea TE, Stanford R, Hagiwara M, Edelsberg JS, Oster G. Death and hospitalization in heart failure patients receiving carvedilol vs. metoprolol tartrate. Int J Cardiol 2005; 99: 117-24.
22. Gehr TW, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999; 55: 269-77.
23. Butler J, Khadim G, Belue R et al. Tolerability to beta-blocker therapy among heart failure patients in clinical practice. J Card Fail 2003; 9: 203-9.
24. Johnson D, Jin Y, Quan H, Cujec B. Beta-blockers and angiotensin- converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada. J Am Coll Cardiol 2003; 42: 1438-45.
25. Wyse DG, Slee A, Epstein AE et al. Are there alternatives to mortality as an endpoint in clinical trials of atrial fibrillation? Heart Rhythm 2004; 1: 531-7.